West Pharmaceutical Services Files 8-K
Ticker: WST · Form: 8-K · Filed: Dec 13, 2024 · CIK: 105770
Sentiment: neutral
Topics: regulatory-filing, financial-statements
TL;DR
WEST files 8-K with financial docs, no major news.
AI Summary
On December 9, 2024, West Pharmaceutical Services, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing indicates that West Pharmaceutical Services is fulfilling its regulatory reporting obligations by submitting financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any new risks or material changes.
Key Numbers
- 1-8036 — Commission File Number (SEC filing identifier)
- 23-1210010 — IRS Employer Identification No. (Company tax identifier)
Key Players & Entities
- WEST PHARMACEUTICAL SERVICES, INC. (company) — Registrant
- Pennsylvania (jurisdiction) — State of incorporation
- 530 Herman O. West Drive (address) — Principal executive offices
- Exton, PA (location) — City, State of principal executive offices
- December 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report other events and to submit financial statements and exhibits.
What is the exact name of the registrant?
The exact name of the registrant is WEST PHARMACEUTICAL SERVICES, INC.
In which state was West Pharmaceutical Services, Inc. incorporated?
West Pharmaceutical Services, Inc. was incorporated in Pennsylvania.
What is the address of the principal executive offices?
The address of the principal executive offices is 530 Herman O. West Drive, Exton, PA 19341-1147.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is December 9, 2024.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-13 16:02:06
Key Financial Figures
- $0.25 — ich registered Common Stock, par value $0.25 per share WST New York Stock Exchange
Filing Documents
- wst-20241209.htm (8-K) — 31KB
- wst-20241209_g1.jpg (GRAPHIC) — 17KB
- 0000105770-24-000088.txt ( ) — 199KB
- wst-20241209.xsd (EX-101.SCH) — 2KB
- wst-20241209_lab.xml (EX-101.LAB) — 21KB
- wst-20241209_pre.xml (EX-101.PRE) — 12KB
- wst-20241209_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 9, 2024, the Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2025. The Company's previously-authorized share repurchase program is expected to expire by December 31, 2024.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 104 The cover page from the Company's Current Report on Form 8-K, dated December 9, 2024, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEST PHARMACEUTICAL SERVICES, INC. /s/ Kimberly Banks MacKay Kimberly Banks MacKay Senior Vice President, General Counsel and Secretary December 13, 2024 3 EXHIBIT INDEX Exhibit No. Description 104 The cover page from the Company's Current Report on Form 8-K, dated December 9, 2024, formatted in Inline XBRL. 4